View Older Stories View More Recent Stories

Oct 29, 2024 12:17PM Eli Lilly & Co. (LLY) Reports Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study

Oct 29, 2024 10:59AM Eli Lilly & Co. (LLY) November 1 weekly option implied volatility into quarter results

Oct 29, 2024 06:07AM Eli Lilly & Co. (LLY) call put ratio 1.7 calls to 1 put into quarter results

Oct 28, 2024 11:33AM Eli Lilly & Co. (LLY) Declares $1.30 Quarterly Dividend; 0.6% Yield

Oct 28, 2024 06:46AM Eli Lilly's (LLY) mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease

Oct 25, 2024 06:45AM Eli Lilly & Co. (LLY) Reports EBGLYSS demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupil

Oct 17, 2024 06:07AM Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)

Oct 16, 2024 11:00AM This pharma stock could deliver a beat and raise quarter, according to Wells Fargo

Oct 14, 2024 08:24AM Hims & Hers (HIMS) Climbs as FDA to Reconsider Decision Barring Compounded Versions of Eli Lilly (LLY) Weight Loss Drug

Oct 14, 2024 06:45AM Eli Lilly & Co. (LLY) reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease

Oct 14, 2024 06:19AM Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)

Oct 10, 2024 07:06AM Eli Lilly (LLY) PT Raised to $1,033 at Truist Securities

Oct 8, 2024 02:25PM Obesity Drug Coverage Could Boost Spending By $35B Through 2034: CBO

Oct 7, 2024 09:18AM TD Cowen Reiterates Buy Rating on Eli Lilly (LLY)

Oct 3, 2024 11:12AM Attor­ney Gen­er­al Ken Pax­ton Sues Big Phar­ma Drug Man­u­fac­tur­ers and Phar­ma­cy Ben­e­fit Man­agers for Con­spir­a­cy That Increased Insulin Prices by 1,000%

Oct 3, 2024 07:52AM BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY) After FDA Says Tirzepatide is No Longer on Shortage Lists

Oct 3, 2024 07:27AM Hims & Hers Health (HIMS) Falls 8% as Shortage of Lilly's (LLY) Weight-Loss Drug Ends

Oct 3, 2024 06:15AM Truist Securities Reiterates Buy Rating on Eli Lilly (LLY)

Oct 3, 2024 06:11AM Deutsche Bank Reiterates Buy Rating on Eli Lilly (LLY)

Oct 2, 2024 08:27AM BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)

Oct 2, 2024 07:31AM Eli Lilly & Co. (LLY) announces $4.5B investment to create the Lilly Medicine Foundry

Oct 2, 2024 06:32AM Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)

Sep 27, 2024 03:10PM FDA Oks Eli Lilly's (LLY) Selpercatinib For Medullary Thyroid Cancer - Bloomberg

Sep 25, 2024 06:46AM Eli Lilly & Co. (LLY) reports new data showing EBGLYSS provided sustained disease control for up to three years in more than 80% of adults and adolescents

Sep 24, 2024 04:49AM Eli Lilly & Co. (LLY) option IV flat

Sep 20, 2024 12:04PM FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices

Sep 20, 2024 11:37AM Deutsche Bank on Eli Lilly (LLY): 'CB-1 Appetite Suppression Looks Underwhelming'

Sep 20, 2024 11:03AM Eli Lilly (LLY) call put ratio 2.1 calls to 1 put as share price up 1.9%

Sep 20, 2024 09:23AM Eli Lilly & Co. (LLY) gains after Novo Nordisk's monlunabant obesity data

Sep 19, 2024 05:53AM Eli Lilly & Co. (LLY) option IV near lower end of range

Sep 17, 2024 02:00PM JPMorgan refreshed its U.S. Analyst Focus List and added these four names

Sep 13, 2024 04:09PM Eli Lilly & Co. (LLY) Announces FDA Approval of EBGLYSS for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Sep 13, 2024 01:04PM Citi restarts coverage of Eli Lilly with Buy rating on increased tirzepatide forecasts

Sep 13, 2024 08:55AM BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)

Sep 13, 2024 03:28AM Citi Resumes Eli Lilly (LLY) at Buy

Sep 12, 2024 06:06AM Eli Lilly & Co. (LLY) Announces $1.8B investment in manufacturing in Ireland

Sep 11, 2024 11:50AM Roche Says Obesity Pill’s Side Effects Blunted by Gradual Dosing - Bloomberg

Sep 11, 2024 07:27AM Novo Nordisk (NVO) gains after oral amycretin presentation

Sep 10, 2024 11:20AM Lilly (LLY): Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes

Sep 9, 2024 07:00PM Piper Sandler answers: who has the best obesity drug of all?

Sep 9, 2024 06:45AM Eli Lilly & Co. (LLY) Appoints Lucas Montarce as CFO

Sep 6, 2024 09:13AM TD Cowen Reiterates Buy Rating on Eli Lilly (LLY)

Sep 5, 2024 06:46AM Eli Lilly & Co. (LLY) reports positive topline results from the QWINT-1 and QWINT-3 phase 3 trials

Sep 5, 2024 06:46AM Eli Lilly & Co. (LLY) reports positive topline results from the QWINT-1 and QWINT-3 phase 3 trials

Sep 4, 2024 08:11AM HAYA Therapeutics Announces Collaboration with Lilly (LLY) to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform

Sep 4, 2024 06:12AM Eli Lilly & Co. (LLY) and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries

Aug 27, 2024 01:37PM Truist Defending Viking Therapeutics (VKTX): 'recommend investors take advantage of today’s selloff to add to shares'

Aug 27, 2024 10:26AM Deutsche Bank on Eli Lilly (LLY): 'Zep Going (Lilly) Direct to Vials Helps Bridge GLP-1 Supply/Demand'

Aug 27, 2024 10:04AM Eli Lilly & Co. (LLY) call put ratio 2.9 calls to 1 put after launches single-dose vials of Zepbound

Aug 27, 2024 08:30AM BMO Capital on Eli Lilly (LLY): 'Positive read through to shares with the company taking a meaningful step to improve access for patients'

View More Recent Stories View Older Stories